Wealthfront Advisers’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.2M | Sell |
672,665
-151,684
| -18% | -$3.97M | 0.03% | 193 |
|
|
2026
Q1 | $23.1M | Buy |
824,349
+134,523
| +20% | +$3.58M | 0.05% | 122 |
|
|
2025
Q4 | $17.2M | Buy |
689,826
+110,462
| +19% | +$2.79M | 0.04% | 153 |
|
|
2025
Q3 | $14.8M | Sell |
579,364
-40,087
| -6% | -$989K | 0.03% | 165 |
|
|
2025
Q2 | $15M | Sell |
619,451
-89,569
| -13% | -$2.09M | 0.04% | 151 |
|
|
2025
Q1 | $18M | Buy |
709,020
+6,458
| +0.9% | +$169K | 0.05% | 114 |
|
|
2024
Q4 | $18.6M | Buy |
702,562
+182,145
| +35% | +$4.94M | 0.05% | 107 |
|
|
2024
Q3 | $15.1M | Buy |
520,417
+65,494
| +14% | +$1.91M | 0.05% | 119 |
|
|
2024
Q2 | $12.7M | Sell |
454,923
-148,889
| -25% | -$4.1M | 0.04% | 125 |
|
|
2024
Q1 | $16.8M | Buy |
603,812
+277,125
| +85% | +$7.69M | 0.06% | 96 |
|
|
2023
Q4 | $9.41M | Buy |
326,687
+233,033
| +249% | +$7.04M | 0.04% | 142 |
|
|
2023
Q3 | $3.11M | Sell |
93,654
-137,387
| -59% | -$4.86M | 0.01% | 323 |
|
|
2023
Q2 | $8.47M | Buy |
231,041
+8,274
| +4% | +$322K | 0.04% | 145 |
|
|
2023
Q1 | $9.09M | Sell |
222,767
-236,669
| -52% | -$10.2M | 0.04% | 127 |
|
|
2022
Q4 | $23.5M | Sell |
459,436
-4,652
| -1% | -$223K | 0.11% | 50 |
|
|
2022
Q3 | $20.3M | Sell |
464,088
-145,890
| -24% | -$7.09M | 0.11% | 52 |
|
|
2022
Q2 | $32M | Buy |
609,978
+187,053
| +44% | +$9.53M | 0.16% | 39 |
|
|
2022
Q1 | $21.9M | Sell |
422,925
-6,640
| -2% | -$345K | 0.1% | 51 |
|
|
2021
Q4 | $25.4M | Buy |
429,565
+132,478
| +45% | +$6.56M | 0.11% | 40 |
|
|
2021
Q3 | $12.8M | Buy |
297,087
+53,719
| +22% | +$2.38M | 0.06% | 65 |
|
|
2021
Q2 | $9.53M | Buy |
243,368
+37,230
| +18% | +$1.45M | 0.05% | 76 |
|
|
2021
Q1 | $7.47M | Sell |
206,138
-16,129
| -7% | -$573K | 0.04% | 92 |
|
|
2020
Q4 | $8.18M | Buy |
222,267
+52,964
| +31% | +$1.94M | 0.05% | 68 |
|
|
2020
Q3 | $5.89M | Buy |
169,303
+18,665
| +12% | +$654K | 0.04% | 76 |
|
|
2020
Q2 | $4.67M | Buy |
150,638
+33,828
| +29% | +$1.15M | 0.04% | 83 |
|
|
2020
Q1 | $3.62M | Sell |
116,810
-32,737
| -22% | -$1.12M | 0.03% | 86 |
|
|
2019
Q4 | $5.56M | Buy |
149,547
+25,469
| +21% | +$907K | 0.04% | 77 |
|
|
2019
Q3 | $4.23M | Sell |
124,078
-79,914
| -39% | -$2.91M | 0.04% | 82 |
|
|
2019
Q2 | $8.38M | Buy |
203,992
+6,452
| +3% | +$256K | 0.07% | 50 |
|
|
2019
Q1 | $7.96M | Sell |
197,540
-61,068
| -24% | -$2.45M | 0.07% | 47 |
|
|
2018
Q4 | $10.7M | Buy |
+258,608
| New | +$10.7M | 0.11% | 38 |
|
Other funds holding PFE
Wealthfront Advisers's PFE Position: Q2 2026 in Review
Wealthfront Advisers reduced its Pfizer (PFE) stake by 18% in Q2 2026, selling an estimated $3.97M and leaving 672,665 shares worth $16.2M. The position accounts for 0.03% of the portfolio, ranked #193.
Wealthfront Advisers first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $32M in Q2 2022. 2,239 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Wealthfront Advisers held 672,665 shares of Pfizer worth $16.2M as of Q2 2026.
- Wealthfront Advisers sold 151,684 Pfizer shares in Q2 2026, an estimated $3.97M.
- Pfizer made up 0.03% of Wealthfront Advisers's portfolio in Q2 2026, its #193 holding.
- Wealthfront Advisers first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Pfizer position peaked at $32M in Q2 2022.
- 2,239 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.